Haemostatix’s topical haemostat technology is based upon the company’s proprietary fibrinogen-binding peptide coupled to a soluble carrier protein. The product binds multiple fibrinogen molecules which act as bridges to form a matrix (Figure A). Studies indicate that the gel is flexible, yet robust, with potential applications as a novel topical haemostat / wound sealant. The product has two key differentiators compared to existing topical haemostats / wound sealants: (i) does not require the addition of the enzyme thrombin or undesirable chemical cross-linkers; (ii) has a robust yet more flexible, open structure compared to fibrin matrices. There is also great potential to vary the functionality of the gel by altering the size and ratio of the carrier protein, linker and peptide components. Haemostatix’s technology is, in effect, a new tool-box to apply to the field of topical haemostasis and wound sealing.

A.

|	Created by One Vision Ltd